Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer.
Messaritakis I, Sfakianaki M, Papadaki C, Koulouridi A, Vardakis N, Koinis F, Hatzidaki D, Georgoulia N, Kladi A, Kotsakis A, Souglakos J, Georgoulias V. Messaritakis I, et al. Among authors: sfakianaki m. Cancer Chemother Pharmacol. 2018 Nov;82(5):767-775. doi: 10.1007/s00280-018-3666-9. Epub 2018 Aug 9. Cancer Chemother Pharmacol. 2018. PMID: 30094617
Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer.
Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, Mavroudis D, Georgoulias V, Souglakos J. Vardakis N, et al. Among authors: sfakianaki m. Clin Cancer Res. 2011 Jan 1;17(1):165-73. doi: 10.1158/1078-0432.CCR-10-0565. Epub 2010 Nov 11. Clin Cancer Res. 2011. PMID: 21071514
Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients.
Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. Saridaki Z, et al. Among authors: sfakianaki m. PLoS One. 2011 Jan 20;6(1):e15980. doi: 10.1371/journal.pone.0015980. PLoS One. 2011. PMID: 21283802 Free PMC article.
ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.
Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. Papadaki C, et al. Among authors: sfakianaki m. J Thorac Oncol. 2012 Apr;7(4):663-71. doi: 10.1097/JTO.0b013e318244bdd4. J Thorac Oncol. 2012. PMID: 22425915 Free article.
Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.
Karachaliou N, Papadaki C, Lagoudaki E, Trypaki M, Sfakianaki M, Koutsopoulos A, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. Karachaliou N, et al. Among authors: sfakianaki m. PLoS One. 2013 Sep 13;8(9):e74611. doi: 10.1371/journal.pone.0074611. eCollection 2013. PLoS One. 2013. PMID: 24058603 Free PMC article.
BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome.
Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. Saridaki Z, et al. Among authors: sfakianaki m. PLoS One. 2013 Dec 18;8(12):e84604. doi: 10.1371/journal.pone.0084604. eCollection 2013. PLoS One. 2013. PMID: 24367680 Free PMC article.
PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, Voutsina A, Koutsopoulos A, Mavroudis D, Georgoulias V, Souglakos J. Papadaki C, et al. Among authors: sfakianaki m. Br J Cancer. 2014 Oct 28;111(9):1757-64. doi: 10.1038/bjc.2014.492. Epub 2014 Sep 18. Br J Cancer. 2014. PMID: 25233397 Free PMC article.
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, Lagoudaki E, Giannikaki L, Kalykaki A, Kontopodis E, Saridaki Z, Malamos N, Georgoulias V, Souglakos J. Pontikakis S, et al. Among authors: sfakianaki m. Pharmacogenomics J. 2017 Dec;17(6):506-514. doi: 10.1038/tpj.2016.63. Epub 2016 Oct 25. Pharmacogenomics J. 2017. PMID: 27779244
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer.
Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, Menis J, Koutsopoulos A, Trypaki M, Tsakalaki E, Sfakianaki M, Hasan B, Stathopoulos E, Georgoulias V, Souglakos J. Tryfonidis K, et al. Among authors: sfakianaki m. Pharmacogenomics J. 2019 Feb;19(1):15-24. doi: 10.1038/s41397-018-0013-9. Epub 2018 Feb 22. Pharmacogenomics J. 2019. PMID: 29472587
34 results